#USA #Labcorp #FDA Approved #Burlington, North Carolina #Fentanyl Test

Labcorp's Revolutionary Fentanyl Test

In a groundbreaking move aimed at enhancing emergency healthcare, Labcorp (NYSE: LH), a prominent figure in laboratory services, has launched the Labcorp Fentanyl Urine Visual Test. This rapid test is the first of its kind to receive clearance from the U.S. Food and Drug Administration (FDA) and is manufactured domestically. The innovative device delivers results in just 10 minutes, enabling healthcare professionals to act swiftly in situations where every second is crucial.

The Urgent Need for Fast Testing

Fentanyl, a potent synthetic opioid, continues to pose a significant risk in various clinical settings, particularly in emergency departments, hospitals, and clinics. Labcorp's analysis indicates that during 2024 and 2025, roughly 4% of pre-employment screenings were positive for fentanyl. Additionally, nearly 10% of individuals in treatment for opioid use disorders tested positive for this substance.

Guidance from the Association for Diagnostics and Laboratory Medicine (ADLM) underscores the critical need for reliable screening tools, particularly as synthetic opioids like fentanyl become more prevalent. The insistence on rapid and dependable testing has become a necessity in urgent care.

Key Features of the Labcorp Fentanyl Urine Visual Test

The Labcorp Fentanyl Urine Visual Test detects norfentanyl, the primary metabolite of fentanyl, which can linger in urine for up to 48 hours post-exposure. This extended detection window is crucial compared to fentanyl itself, which may clear from the system within hours. Furthermore, the test meets FDA standards for use in Clinical Laboratory Improvement Amendments (CLIA)-certified environments, making it a reliable option for preliminary rapid screening.

While the rapid test provides initial results, healthcare providers are advised to follow up with more comprehensive laboratory methods to confirm findings, adhering to standard rapid testing protocols.

Labcorp Point of Care Initiative

As part of its commitment to improving accessibility to critical health services, the Labcorp Fentanyl Urine Visual Test will be distributed through Labcorp Point of Care, previously recognized as MEDTOX Diagnostics. In 2026, the company's branding and packaging will transition to symbolize its integration into the Labcorp family.

Enhancing Emergency Response

Dr. Brian Caveney, the Chief Medical and Scientific Officer at Labcorp, emphasized, "When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care. The Labcorp Fentanyl Urine Visual Test delivers results in minutes, helping teams respond quickly and confidently, ultimately supporting better patient outcomes."

This rapid testing capability is crucial in scenarios where patients may present with overwhelming symptoms indicative of fentanyl exposure. Quick detection allows medical teams to initiate appropriate treatments without delay, potentially saving lives.

About Labcorp

Labcorp is renowned for its innovative and comprehensive laboratory services, aiding healthcare professionals across various sectors in making informed decisions. With a workforce of nearly 71,000 employees, Labcorp serves clients in approximately 100 countries, supporting the approval of more than 85% of new drugs by the FDA in 2025 alone. The organization runs over 750 million tests annually to facilitate optimal patient care worldwide.

For more information about the Labcorp Fentanyl Urine Visual Test, visit Labcorp Point of Care.

In summary, Labcorp's unveiling of the Fentanyl Urine Visual Test marks a significant advancement in rapid testing methodologies, reinforcing the importance of timely and effective responses in emergency healthcare settings. With the nation grappling with the opioid crisis, this innovative testing solution promises to be a game-changer for health professionals on the front lines of care.